CNTB
Income statement / Annual
Last year (2025), Connect Biopharma Holdings Ltd's total revenue was $64.00 K,
a decrease of 99.75% from the previous year.
In 2025, Connect Biopharma Holdings Ltd's net income was -$55.48 M.
See Connect Biopharma Holdings Ltd,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$64.00 K |
$26.03 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$64.00 K
|
$26.03 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$37.80 M
|
$29.26 M
|
$53.00 M
|
$96.63 M
|
$80.50 M
|
$23.12 M
|
$15.44 M
|
| General & Administrative Expenses |
$20.34 M
|
$19.23 M
|
$16.05 M
|
$20.81 M
|
$19.01 M
|
$7.31 M
|
$1.41 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$20.34 M
|
$19.23 M
|
$16.05 M
|
$20.81 M
|
$19.01 M
|
$7.31 M
|
$1.41 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$1.88 M
|
-$1.40 M
|
-$88.74 M
|
-$8.62 M
|
| Operating Expenses |
$58.14 M
|
$48.49 M
|
$69.06 M
|
$119.32 M
|
$98.11 M
|
$29.36 M
|
$16.44 M
|
| Cost And Expenses |
$58.14 M
|
$48.49 M
|
$69.06 M
|
$119.32 M
|
$98.11 M
|
$29.36 M
|
$16.44 M
|
| Interest Income |
$2.27 M
|
$4.45 M
|
$5.20 K
|
$1.56 M
|
$97.67 K
|
$109.84 K
|
$154.65 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$21.03 K
|
$6.91 K
|
$6.43 K
|
$7.69 K
|
| Depreciation & Amortization |
$704.00 K
|
$660.00 K
|
$720.00 K
|
$1.03 M
|
$634.00 K
|
$221.05 K
|
$114.61 K
|
| EBITDA |
-$57.37 M |
-$21.79 M |
-$68.34 M |
-$116.74 M |
-$201.36 M |
-$118.21 M |
-$24.78 M |
| EBITDA Ratio |
-896.41
|
-0.84
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-907.41
|
-0.86
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$2.79 M
|
$7.05 M
|
$7.07 M
|
$1.52 M
|
-$103.89 M
|
-$89.68 M
|
-$8.17 M
|
| Income Before Tax |
-$55.28 M
|
-$15.41 M
|
-$61.99 M
|
-$117.79 M
|
-$202.00 M
|
-$119.37 M
|
-$24.46 M
|
| Income Before Tax Ratio |
-863.8
|
-0.59
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$197.00 K
|
$223.00 K
|
$120.00 K
|
$298.00 K
|
$266.00 K
|
$0.00
|
$0.00
|
| Net Income |
-$55.48 M
|
-$15.63 M
|
-$62.11 M
|
-$118.09 M
|
-$202.27 M
|
-$119.37 M
|
-$24.46 M
|
| Net Income Ratio |
-866.88
|
-0.6
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1 |
-0.28 |
-1.08 |
-14.5 |
-25 |
-14.45 |
-3.02 |
| EPS Diluted |
-1 |
-0.28 |
-1.08 |
-14.5 |
-25 |
-14.45 |
-3.02 |
| Weighted Average Shares Out |
$55.66 M
|
$55.21 M
|
$55.07 M
|
$55.04 M
|
$52.27 M
|
$53.94 M
|
$55.82 M
|
| Weighted Average Shares Out Diluted |
$55.66 M
|
$55.21 M
|
$55.07 M
|
$55.04 M
|
$52.27 M
|
$53.94 M
|
$55.82 M
|
| Link |
|
|
|
|
|
|
|
